All In Biotech

Drug Trial Radar · NCT06131437

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 809 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

809

Actual

Start

Nov 27, 2023

Primary completion

Dec 8, 2025

Study completion Jan 9, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.

Conditions

  • Obesity

Interventions

  • CagrilintideDrug

    Cagrilintide will be administered subcutaneously.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously.

  • TirzepatideDrug

    Tirzepatide will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 84)

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Chambliss Clinical Trials LLC

    Montgomery, Alabama

  • FDRC

    Costa Mesa, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Univ of Colorado at Denver

    Aurora, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Northeast Research Institute

    Fleming Island, Florida

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Hope Clin Res & Wellness

    Conyers, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Evanston Premier Hlthcr Res

    Skokie, Illinois

  • Midwest Inst For Clin Res

    Indianapolis, Indiana

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Comprehensive Weight Ctrl Prog

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Medication Mgmnt, LLC_Grnsboro

    Greensboro, North Carolina

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina

  • Accellacare_NC

    Raleigh, North Carolina

  • Accellacare

    Wilmington, North Carolina

  • New Venture Medical Research

    Wadsworth, Ohio

  • Lynn Institute of Norman

    Norman, Oklahoma

  • The University of Penn Center

    Philadelphia, Pennsylvania

  • Clinical Res Collaborative

    Cumberland, Rhode Island

  • Medical University Of South Carolina

    Charleston, South Carolina

  • Coastal Carolina Res Ctr

    North Charleston, South Carolina

  • Hillcrest Clinical Research

    Simpsonville, South Carolina

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Holston Medical Group_Bristol

    Bristol, Tennessee

  • Holston Medical Group

    Kingsport, Tennessee

  • Amarillo Med Spec LLP

    Amarillo, Texas

  • Elligo Clin Res Centre

    Austin, Texas

  • UT Health University of Texas

    Bellaire, Texas

  • Baylr Sctt White Rs Inst, Endo

    Dallas, Texas

  • Velocity Clin Res, Dallas

    Dallas, Texas

  • UT Southwestern Medical Center-CRU

    Dallas, Texas

  • DCOL Ctr for Clin Res

    Longview, Texas

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.